Inflation is rapidly eroding our purchasing power and consuming our wealth. Here is a powerful antidote for investors.
Exploring the companies and themes that make up this emerging and exciting new sector
Hollister Biosciences Inc. Announces Private Placement Financing of Up to $1.5 Million
Hollister Biosciences announces a private placement for CAD$1.5 million, expected to close by July 12, 2020.
Red Light Holland Names Medical and Scientific Division
Red Light Holland makes move into medicinal psychedelic applications.
Psychedelics: A Better Way To Treat Depression
Psychedelic drugs represent a potentially enormous step forward in treating an epidemic for which there are currently no good treatment options.
MindMed And Eleusis Lead The Way In Psychedelics Micro-Dosing Research
Given that psychedelics micro-dosing has several commercial advantages, here are two companies that investors should look at.
Osoyoos Announces Agreement to Acquire AI Pharmaceuticals Jamaica Limited
Osoyoos cannabis has acquired a psilocybin-focuse biopharma company based in Jamaica.
Champignon Provides Corporate Update, Announces Name Change, Rebranding and Planned Spin Out
Champignon Brands is proposing changing its corporate name to Apotheosis Scientific Ltd, and announces a planned spin-off its consumer packaged goods (CPG) division.
Red Light Holland Announces The Closing of Second Tranche of Private Placement
With the closing of its second tranche, Red Light Holland has now raised $3,830,529 in its current private placement.
Canadians More Receptive To Use Of Psilocybin For The Terminally Ill: New Poll
Canadians are rapidly warming up to the idea of using psilocybin to reduce distress among the terminally ill.
ATAI launches IntroSpect Digital Therapeutics, Appoints veteran software engineer David Keene as CEO
ATAI is adding a digital therapeutics division to its R&D platform.
MindMed To Evaluate Ayahuasca's Active Ingredient DMT In A Phase 1 Clinical Trial Collaboration
MindMed is adding to its clinical trials on psychedelics with a Phase 1 collaboration aimed at ayahuasca research.
GreenStar Biosciences Signs Agreement to Acquire 100% of Eleusian Biosciences Corp.
Greenstar Biosciences is entering the psychedelics space via its acquisition of Eleusian Biosciences Corp.